H.C. Wainwright analyst Sean Lee raised the firm’s price target on Corvus Pharmaceuticals (CRVS) to $27 from $11 and keeps a Buy rating on the shares after the company announced “game-changing” topline results from Cohort 4 of the Phase 1 study of soquelitinib for the treatment of refractory atopic dermatitis. Based on the findings, the firm is increasing its projected market penetration to 30% from 10%, the analyst tells investors.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRVS:
- Corvus Pharmaceuticals reports positive Phase 1 soquelitinib results
- Corvus announces results from cohort 4 of Phase 1 trial of soquelitinib
- Corvus Pharmaceuticals confirms plans to announce results of Soquelitinib trial
- Corvus presents final data from soquelitinib Phase 1/1b T cell lymphoma trial
- Corvus Pharmaceuticals management to meet with Cantor